ALK and non-small cell lung carcinoma: The evidence of anaplastic lymphoma kinase (ALK) inhibitor for non-small cell lung cancer (NSCLC) harbouring sperm antigen with calponin homology and coiled-coil domains 1-like (<i>SPECC1L</i>)-<i>ALK</i> fusion was limited.